MYCN and neuroblastoma: Consequently, while further studies are required to assess the clinical safety and efficacy of M344 before use in humans, our analysis of HDAC transcripts in NB samples suggest that in the treatment of NB, patients with advanced-stage tumors, regardless of MYCN status, may receive the most substantial benefit from HDAC inhibitor therapy.